Matthew Blackman

Orthopediatrics Corp (NASDAQ: KIDS) is poised to achieve strong top-line growth due to its exclusive focus on the sizeable and largely underserved $2.5 billion pediatric orthopedic market, according to Stifel.  Stifel initiated coverage of Orthopediatrics with a Buy rating and a $23 price...

Following the announcement by Endologix, Inc. (NASDAQ: ELGX) that it will no longer seek approval of the Nellix first generation device following a FDA meeting, Stifel said the potential U.S. approval is pushed to at least 2020 from the previous timeline of early-2018. The company would now...